{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:37:27Z","timestamp":1789000647862,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"DOI":"10.7759\/cureus.25486","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T14:21:41Z","timestamp":1653920501000},"source":"Crossref","is-referenced-by-count":13,"title":["Non-bacterial Cystitis With Increased Expression of Programmed Cell Death Ligand 1 in the Urothelium: An Unusual Immune-Related Adverse Event After Atezolizumab Administration for Metastatic Breast Cancer"],"prefix":"10.7759","author":[{"given":"Aiko","family":"Obayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Hamada-Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat S","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al.. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016, 27:559-74. 10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788629","article-title":"A case report of non-bacterial cystitis caused by immune checkpoint inhibitors","volume":"12","author":"Zhu S","year":"2021","unstructured":"Zhu S, Bian L, Lv J, Liu B, Shen J. A case report of non-bacterial cystitis caused by immune checkpoint inhibitors. Front Immunol. 2021, 12:788629. 10.3389\/fimmu.2021.788629","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0298-6","article-title":"A case of cystitis after administration of nivolumab","volume":"6","author":"Ozaki K","year":"2017","unstructured":"Ozaki K, Takahashi H, Murakami Y, Kiyoku H, Kanayama H. A case of cystitis after administration of nivolumab. Int Cancer Conf J. 2017, 6:164-6. 10.1007\/s13691-017-0298-6","journal-title":"Int Cancer Conf J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2017.12.006","article-title":"Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor","volume":"17","author":"Shimatani K","year":"2018","unstructured":"Shimatani K, Yoshimoto T, Doi Y, Sonoda T, Yamamoto S, Kanematsu A. Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor. Urol Case Rep. 2018, 17:97-9. 10.1016\/j.eucr.2017.12.006","journal-title":"Urol Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S321965","article-title":"Immunotherapy-related cystitis: case report and review of the literature","volume":"14","author":"Zhu L","year":"2021","unstructured":"Zhu L, Wang Z, Stebbing J, Wang Z, Peng L. Immunotherapy-related cystitis: case report and review of the literature. Onco Targets Ther. 2021, 14:4321-8. 10.2147\/OTT.S321965","journal-title":"Onco Targets Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12211","article-title":"Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: an unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma","volume":"3","author":"Ueki Y","year":"2020","unstructured":"Ueki Y, Matsuki M, Kubo T, et al.. Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: an unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma. IJU Case Rep. 2020, 3:266-9. 10.1002\/iju5.12211","journal-title":"IJU Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757069","article-title":"Case report: a case of sintilimab-induced cystitis\/ureteritis and review of sintilimab-related adverse events","volume":"11","author":"Tu L","year":"2021","unstructured":"Tu L, Ye Y, Tang X, Liang Z, You Q, Zhou J, Pan Z. Case report: a case of sintilimab-induced cystitis\/ureteritis and review of sintilimab-related adverse events. Front Oncol. 2021, 11:757069. 10.3389\/fonc.2021.757069","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000765","article-title":"Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma","volume":"31","author":"Schneider S","year":"2021","unstructured":"Schneider S, Alezra E, Yacoub M, Ducharme O, Gerard E, Dutriaux C, Prey S. Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma. Melanoma Res. 2021, 31:487-9. 10.1097\/CMR.0000000000000765","journal-title":"Melanoma Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23459","article-title":"Expression of programmed death ligand-1 on bladder tissues is detected in a clinically and histologically well-defined interstitial cystitis cohort","volume":"37","author":"Chen Y","year":"2018","unstructured":"Chen Y, Yu W, Yang Y, et al.. Expression of programmed death ligand-1 on bladder tissues is detected in a clinically and histologically well-defined interstitial cystitis cohort. Neurourol Urodyn. 2018, 37:1396-404. 10.1002\/nau.23459","journal-title":"Neurourol Urodyn"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81577-non-bacterial-cystitis-with-increased-expression-of-programmed-cell-death-ligand-1-in-the-urothelium-an-unusual-immune-related-adverse-event-after-atezolizumab-administration-for-metastatic-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:40Z","timestamp":1707507340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81577-non-bacterial-cystitis-with-increased-expression-of-programmed-cell-death-ligand-1-in-the-urothelium-an-unusual-immune-related-adverse-event-after-atezolizumab-administration-for-metastatic-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.25486","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,30]]}}}